AVEO Pharma Raises $53 Million

AVEO Pharmaceuticals Inc., a Cambridge, Mass.-based oncology drug company, has raised $53 million in Series D funding. New investors include: Biogen Idec, Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group and Vatera Holdings, an investment vehicle owned by Kos Pharma founder Michael Jaharis. Return backers include: Highland Capital Partners, Venrock Associates, MPM Capital, Prospect Ventures, Flagship Ventures, Oxford Bioscience Partners, Greylock Partners, Lotus Biosciences and GE Capital. AVEO had raised $63.2 million in VC funding, plus $15 million in venture debt from Hercules Technology Growth Capital. www.aveopharma.com